NUFORMIX PLC
Repurposing drugs for fibrosis and oncology using proprietary cocrystal technology.
NFX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYW79Y38
- LEI:
- 2138003XG3H3I2J3BJ24
- Country:
- United Kingdom
- Address:
- 6TH FLOOR, EC3V 0HR LONDON
- Website:
- https://www.nuformix.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Nuformix PLC is a pharmaceutical development company that specializes in drug repurposing to address unmet medical needs, primarily in fibrosis and oncology. The company leverages its proprietary cocrystal technology to unlock and enhance the therapeutic potential of known, approved drugs. This approach aims to improve the physical properties of existing medicines, thereby creating a pipeline of novel treatments for its target therapeutic areas.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-07 12:31 |
Share Issue/Capital Change
Circular - UNDERWRITTEN OPEN OFFER OF 114,040,535 OPEN OFFER SHARES AT 0.2 PENC…
|
English | 593.0 KB | ||
| 2025-10-10 08:00 |
Board/Management Information
Change of Auditor
|
English | 9.3 KB | ||
| 2025-08-11 08:00 |
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
|
English | 13.5 KB | ||
| 2025-05-29 08:00 |
Regulatory News Service
Confirmation of European ODD for NXP002
|
English | 13.6 KB | ||
| 2025-05-28 11:28 |
Prospectus
Nuformix plc - Single prospectus
|
English | 866.5 KB | ||
| 2025-05-23 14:19 |
Prospectus
Prospectus
|
English | 866.5 KB | ||
| 2025-05-23 14:08 |
Report Publication Announcement
Publication of a Prospectus
|
English | 13.3 KB | ||
| 2025-02-28 13:30 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 9.3 KB | ||
| 2025-02-14 15:18 |
Report Publication Announcement
Posting of Annual Report and Notice of AGM
|
English | 8.4 KB | ||
| 2025-01-30 08:00 |
Share Issue/Capital Change
£168,750 Placing
|
English | 13.1 KB | ||
| 2025-01-29 08:00 |
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
|
English | 414.7 KB | ||
| 2025-01-28 08:00 |
Regulatory News Service
NXP002 ODD Application Submitted
|
English | 11.4 KB | ||
| 2025-01-13 08:00 |
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
|
English | 9.6 KB | ||
| 2024-11-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 9.1 KB | ||
| 2024-11-05 15:25 |
Director's Dealing
Director/PDMR Dealings
|
English | 39.9 KB |
Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NUFORMIX PLC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
%20Inc./other/Mind_Medicine_MindMed_Inc.-logo.png){kind=logo}
